

# Helene Beaudry

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10402200/publications.pdf>

Version: 2024-02-01

8  
papers

602  
citations

1307594

7  
h-index

1588992

8  
g-index

8  
all docs

8  
docs citations

8  
times ranked

815  
citing authors

#	ARTICLE	IF	CITATIONS
1	Design, Synthesis, and Biological Evaluation of the First Selective Nonpeptide AT <sub>2</sub> Receptor Agonist. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 5995-6008.	6.4	317
2	Optogenetic Silencing of Na <sup>v</sup> 1.8-Positive Afferents Alleviates Inflammatory and Neuropathic Pain. <i>ENeuro</i> , 2016, 3, ENEURO.0140-15.2016.	1.9	107
3	Distinct behavioral responses evoked by selective optogenetic stimulation of the major TRPV1+ and MrgD+ subsets of C-fibers. <i>Pain</i> , 2017, 158, 2329-2339.	4.2	63
4	New Selective AT <sub>2</sub> Receptor Ligands Encompassing a $\beta$ -Turn Mimetic Replacing the Amino Acid Residues 4 <sup>th</sup> -5 of Angiotensin II Act as Agonists. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 4009-4024.	6.4	41
5	Selective angiotensin II AT <sub>2</sub> receptor agonists: Benzamide structure-activity relationships. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 6841-6849.	3.0	29
6	Involvement of Protein Kinase C $\alpha$ (PKC $\alpha$ ) in the Early Action of Angiotensin II Type 2 (AT <sub>2</sub> ) Effects on Neurite Outgrowth in NG108 $\alpha$ 15 Cells: AT <sub>2</sub> -Receptor Inhibits PKC $\alpha$ and p21ras Activity. <i>Endocrinology</i> , 2006, 147, 4263-4272.	2.8	20
7	Short pseudopeptides containing turn scaffolds with high AT <sub>2</sub> receptor affinity. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 5963-5972.	3.0	18
8	Will optogenetics be used to treat chronic pain patients?. <i>Pain Management</i> , 2017, 7, 269-278.	1.5	7